Table 2 Characteristics of Rechallenge Treatment
Rechallenge (n = 128) | |
|---|---|
Chemotherapy, n (%) | |
Oxaliplatin based treatment (FOLFOX/XELOX) | 60 (46.8) |
Irinotecan based treatment (FOLFIRI/XELIRI) | 39 (30.4) |
Irinotecan and oxaliplatin based treatment (FOLFIRINOX) | 23 (17.9) |
Othersa | 6 (4.6) |
Rechallenge chemotherapy regimen (n = 128) | |
Same as first-line, n (%) | 71 (55.5) |
Same as second-line, n (%) | 29 (22.6) |
Both oxaliplatin and irinotecan in rechallenge, n (%) | 22 (17.2) |
Only FU-based, n (%) | 6 (4.7) |
Biological agent combined with chemotherapy, n(%) | |
Anti-VEGF | 76 (59.3) |
Anti-EGFR | 30 (23.4) |
None | 22 (17.2) |
Prior exposure of the biological agent used in rechallenge, (n = 106, %) | |
Yes | 73 (68.9) |
No | 33 (31.1) |
Anti-VEGF in third-line | 10 (30) |
Anti-EGFR (cetuximab/panitumumab) in third-line | 23 (70) |
Prior response to chemotherapy used in rechallenge, n(%) | |
CR + PR + SD | 112 (70.8) |
PD | 16 (29.1) |